Latest News and Press Releases
Want to stay updated on the latest news?
-
New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal...
-
Metagenomi to Present at Upcoming Scientific Meetings
-
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
-
Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
-
Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
-
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
-
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
-
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
-
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
-
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...